If you or someone you love has just been told "it might be myasthenia gravis," the name alone can be intimidating. But the underlying cause, once broken down, is actually a fairly clear story about the immune system attacking the wrong target. This article walks through exactly what goes wrong in the body, why it happens, and what we currently know - and don't know - about why some people develop this condition.
The Short Answer
Myasthenia gravis (MG) is an autoimmune disease in which the immune system mistakenly produces antibodies that attack the connection point between nerves and muscles - called the neuromuscular junction. These antibodies block or destroy the receptors that muscles need to receive the "contract" signal from nerves. The result is fatigable muscle weakness: muscles that work fine at rest but tire and weaken with repeated use.
It is not caused by a problem in the nerves themselves, and it is not caused by a problem in the muscles themselves. The breakdown happens specifically at the junction between the two - and it happens because the immune system has been misdirected.
Understanding the Neuromuscular Junction First
To understand what goes wrong in myasthenia gravis, it helps to understand how muscles normally receive their "move" signal.
When your brain decides to move a muscle, it sends an electrical signal down a nerve. At the very end of that nerve, the signal triggers the release of a chemical messenger called acetylcholine. Acetylcholine crosses a tiny gap and lands on specialized receptors - acetylcholine receptors (AChR) - sitting on the surface of the muscle fiber. When enough acetylcholine binds to enough receptors, the muscle fiber contracts.
This entire docking station - the nerve ending, the gap, and the receptor-studded muscle surface - is called the neuromuscular junction. It is a precise, fast, and normally very reliable system. Myasthenia gravis disrupts it.
The Main Cause: Antibodies Against Acetylcholine Receptors
In the majority of people with myasthenia gravis, the immune system produces antibodies - most commonly IgG1 and IgG3 - that target the acetylcholine receptor itself. These antibodies cause damage in two main ways:
They speed up the removal of receptors. Normally, AChRs sit on the muscle surface for a certain lifespan before being recycled. Antibody binding accelerates this turnover, so receptors are pulled away and degraded faster than the muscle can replace them.
They trigger complement-mediated damage. The antibodies activate a part of the immune system called the complement cascade, which physically damages the muscle membrane surrounding the receptors - flattening and simplifying the folded structure that normally holds a dense array of receptors.
The net effect of both processes is the same: there are fewer functioning acetylcholine receptors available on the muscle surface. Even when the nerve fires normally and releases acetylcholine normally, there are not enough working receptors left to reliably trigger a strong, sustained muscle contraction. Roughly 80 to 85% of all myasthenia gravis patients have these AChR antibodies, making this the dominant and best understood form of the disease.
When It Isn't AChR: MuSK, LRP4, and Agrin
Not everyone with myasthenia gravis has antibodies against the acetylcholine receptor directly. In a meaningful minority of cases, the immune system instead targets proteins that help build and organize the receptor cluster in the first place.
MuSK Antibodies
Muscle-specific kinase (MuSK) is a protein responsible for organizing acetylcholine receptors into a tight, functional cluster on the muscle surface. Antibodies against MuSK - typically of the IgG4 subclass - disrupt this organizing process directly, causing the receptor cluster itself to fall apart, even without necessarily destroying individual receptors. This subtype tends to affect facial, throat, and breathing muscles more prominently than the limbs.
LRP4 and Agrin Antibodies
LRP4 (low-density lipoprotein receptor-related protein 4) is the postsynaptic receptor for a nerve-released protein called agrin. Normally, agrin binds to LRP4, which then activates MuSK, which then organizes acetylcholine receptors into clusters - a coordinated three-step assembly process. Antibodies against LRP4 (and sometimes agrin itself) interrupt this assembly chain before it can properly cluster the receptors, even though the receptors themselves may be entirely normal.
LRP4 antibodies are found in a meaningful share of patients who test negative for both AChR and MuSK antibodies - so-called "double-seronegative" myasthenia gravis - and tend to be associated with milder disease at onset.
Seronegative Myasthenia Gravis
Even after testing for AChR, MuSK, and LRP4 antibodies, roughly 10% of patients have no detectable antibody using current testing methods. This does not mean the disease isn't autoimmune - it likely reflects antibodies that exist but bind too weakly, or to a form of the receptor, that current standard blood tests don't reliably detect. Newer cell-based assays are improving detection rates in this group.
Why Does the Immune System Attack in the First Place? The Role of the Thymus
This is the question patients ask most often, and it is also where the science gets genuinely interesting. The leading explanation centers on a gland most people rarely think about: the thymus.
The thymus is a small organ sitting behind the breastbone, most active in childhood, whose job is to train T cells - a category of immune cell - to recognize the body's own tissue as "self" and leave it alone. This training process, called negative selection, is supposed to eliminate any T cells that would otherwise attack the body's own proteins.
Remarkably, the normal thymus contains small numbers of "myoid cells" that naturally express acetylcholine receptor-like proteins on their surface - essentially a built-in rehearsal copy of the very molecule that becomes the target in myasthenia gravis. In a healthy thymus, this is harmless; it is part of how the immune system normally learns to tolerate AChR as "self."
In many myasthenia gravis patients, something goes wrong with this training process. Thymic tissue from myasthenia gravis patients selectively enhances the production of anti-AChR antibody by the patient's own blood lymphocytes - suggesting the thymus is not just a passive bystander but an active site where the harmful, self-attacking immune response against AChR is generated and amplified.
This is also why thymectomy - surgical removal of the thymus - is an established treatment for many patients with AChR-antibody-positive myasthenia gravis, particularly those with thymic abnormalities. Removing the gland removes a key engine of the abnormal immune response, even though it does not "cure" the disease in a single step.
Thymoma: When a Tumor Is Involved
In a subset of patients, the thymus contains an actual tumor - called a thymoma. Thymoma-associated myasthenia gravis (TAMG) is recognized as a distinct subtype with its own risk profile and disease course, alongside early-onset MG and late-onset MG, which differ by age of onset, sex distribution, and thymic pathology. The thymoma is thought to disrupt normal immune tolerance training even more directly than simple thymic hyperplasia (enlargement), making thymoma screening a standard part of the diagnostic workup for newly diagnosed patients.
Who Is More Likely to Develop Myasthenia Gravis?
Myasthenia gravis is rare. The incidence is estimated at 4.1 to 30 cases per million person-years, with a prevalence of 150 to 200 cases per million - meaning at any given time, roughly 1 in 5,000 to 1 in 6,700 people are living with the condition. Several patterns have emerged in who is affected:
Age and sex follow a bimodal pattern. Early-onset MG (typically before age 50) shows a strong female predominance, while late-onset MG (after 50) affects men and women more equally, and in some populations skews slightly male. This bimodal pattern is one of the clues researchers use to argue that early-onset and late-onset MG may have somewhat different underlying triggers, even though they converge on the same antibody-mediated mechanism.
LRP4-positive disease shows its own pattern. Among patients with LRP4 antibodies specifically, the female-to-male ratio is approximately 2.5 to 1, with average onset around age 33 in women and 42 in men - reinforcing that hormonal and sex-linked immune factors likely play some role, though the precise mechanism remains under investigation.
Genetic and environmental factors both contribute. Variation in geographic occurrence of MG can reflect both genetic background and environmental triggers such as infections, and certain HLA (human leukocyte antigen) gene variants - which influence how the immune system presents proteins to T cells - are more common in people who develop MG. However, no single gene causes the disease; rather, genetic background appears to shift overall susceptibility.
Other autoimmune conditions raise risk. Because MG is fundamentally a disorder of immune tolerance, people who already have one autoimmune condition - such as autoimmune thyroid disease - have a somewhat higher likelihood of developing a second one, including MG. This clustering is common across autoimmune diseases generally and is not unique to myasthenia gravis.
What Triggers a Flare or Worsening of Symptoms?
It is worth distinguishing between what causes the disease in the first place and what causes symptoms to temporarily worsen once someone already has MG. Common aggravating factors include:
- Infections, particularly respiratory infections, which place additional stress on the immune system and on breathing muscles
- Physical or emotional stress
- Certain medications, including some antibiotics, beta-blockers, and anesthesia-related drugs, which can interfere with neuromuscular transmission
- Heat exposure, which can transiently worsen muscle fatigue in many patients
- Pregnancy and the postpartum period, during which immune activity shifts substantially
- Surgery and other major physiologic stressors
None of these factors "cause" myasthenia gravis to develop from scratch; rather, they can unmask or worsen symptoms in someone whose underlying antibody-mediated disease is already present, sometimes before a formal diagnosis has even been made.
What This Means in Practice
Understanding the cause of myasthenia gravis is what allows modern treatment to be so targeted. Because the core problem is "too many harmful antibodies and too much immune activation," most current treatments work by either reducing antibody production, removing existing antibodies from the blood, or compensating for the receptor shortage directly - rather than trying to fix the muscle or nerve, which were never the actual problem.
This is also why thymectomy makes biological sense for many AChR-positive patients, and why researchers continue to study the thymus, B cells, and specific antibody subtypes so closely: understanding precisely where in this chain - thymus, T cell, B cell, antibody, or neuromuscular junction - things go wrong for a given patient is increasingly central to choosing the right treatment for that person specifically.
This article is for educational purposes only and does not constitute medical advice or diagnosis. Myasthenia gravis is a serious condition requiring evaluation and ongoing management by a neurologist. If you or someone you know is experiencing symptoms such as fluctuating muscle weakness, drooping eyelids, double vision, or difficulty swallowing or breathing, please seek prompt medical attention.
Frequently Asked Questions (FAQs)
1. Is myasthenia gravis genetic - can I pass it to my children?
2. What is the difference between AChR-positive and MuSK-positive myasthenia gravis?
3. Does the thymus cause myasthenia gravis, and should it always be removed?
4. Can an infection actually trigger myasthenia gravis to start?
5. Why does muscle weakness in myasthenia gravis get worse with activity and better with rest?
This pattern, called fatigable weakness, follows directly from the underlying mechanism. With fewer functioning acetylcholine receptors available on the muscle surface, each successive nerve signal has a harder time triggering a full contraction as available acetylcholine and receptor binding capacity become temporarily depleted with repeated use. Rest allows acetylcholine stores and receptor availability to partially recover, which is why strength often improves after a break (Gilhus & Verschuuren, 2015).
References
Engebretsen, K. V. T., Skeie, G. O., & Romi, F. (2024). Epidemiology of myasthenia gravis. In International Review of Neurobiology (Vol. 177). Elsevier. https://doi.org/10.1016/bs.irn.2024.10.005
Gilhus, N. E., & Verschuuren, J. J. (2015). Myasthenia gravis: subgroup classification and therapeutic strategies. The Lancet Neurology, 14(10), 1023-1036. https://pmc.ncbi.nlm.nih.gov/articles/PMC4926737/
Kaminski, H. J., Sikorski, P., Coronel, S. I., & Kusner, L. L. (2024). Myasthenia gravis: the future is here. The Journal of Clinical Investigation, 134(12), e179742. https://doi.org/10.1172/JCI179742
Newsom-Davis, J., Vincent, A., Wilson, S. G., & Ward, C. D. (1981). Thymus cells in myasthenia gravis selectively enhance production of anti-acetylcholine-receptor antibody by autologous blood lymphocytes. New England Journal of Medicine, 305(20), 1313-1318. https://doi.org/10.1056/NEJM198111263052203
Punga, A. R., Maddison, P., Heckmann, J. M., Guptill, J. T., & Evoli, A. (2022). Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. The Lancet Neurology, 21(2), 176-188. https://doi.org/10.1016/S1474-4422(21)00297-0
Tzartos, J. S., & Tzartos, S. J. (2014). Antibodies to full-length agrin and LRP4 in myasthenia gravis. PLOS One, 9(3), e91816. https://doi.org/10.1371/journal.pone.0091816
Verschuuren, J. J., Huijbers, M. G., Plomp, J. J., Niks, E. H., Molenaar, P. C., Martinez-Martinez, P., Gilhus, N. E. (2013). Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmunity Reviews, 12(9), 918-923. https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/
Zisimopoulou, P., Evangelakou, P., Tzartos, J., Lazaridis, K., Zouvelou, V., Mantegazza, R., Antozzi, C., Andreetta, F., Evoli, A., Deymeer, F., Saruhan-Direskeneli, G., Squintani, G., Vincent, A., & Tzartos, S. J. (2014). A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. Journal of Autoimmunity, 52, 139-145. https://pubmed.ncbi.nlm.nih.gov/24373505/
